Suspended

Phase II Study of Campath-1H in Lymphoplasmacytic Lymphoma (Waldenstrom's Macroglobulinemia)

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

Data Collection

Who is being recruted

Blood Protein Disorders+14

+ Cardiovascular Diseases

+ Hematologic Diseases

Over 18 Years
See all eligibility criteria
How is the trial designed

Treatment Study

Phase 2
Interventional
Study Start: January 2004
See protocol details

Summary

Principal SponsorJonsson Comprehensive Cancer Center
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: January 1, 2004

Actual date on which the first participant was enrolled.

OBJECTIVES: * Determine the objective response in patients with Waldenstrom's macroglobulinemia treated with alemtuzumab. * Determine the time to treatment failure in patients treated with this drug. * Determine the toxicity of this drug in these patients. OUTLINE: This is a multicenter study. Patients receive alemtuzumab IV over 2 hours on days 1, 3, and 5 of weeks 1-6 (course 1) in the absence of disease progression or unacceptable toxicity. Patients with a complete response undergo observation. Patients with stable disease or a minor or partial response receive an additional course of alemtuzumab, administered as in course 1, on weeks 7-12. Patients are followed every 6 months for 2 years. PROJECTED ACCRUAL: A total of 13-27 patients will be accrued for this study.

Official TitlePhase II Study of Campath-1H in Lymphoplasmacytic Lymphoma (Waldenstrom's Macroglobulinemia)
NCT00081068
Principal SponsorJonsson Comprehensive Cancer Center
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Over 18 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Blood Protein DisordersCardiovascular DiseasesHematologic DiseasesHemic and Lymphatic DiseasesHemorrhagic DisordersImmune System DiseasesImmunoproliferative DisordersLymphatic DiseasesLymphomaLymphoproliferative DisordersWaldenstrom MacroglobulinemiaNeoplasmsNeoplasms by Histologic TypeParaproteinemiasVascular DiseasesHemostatic DisordersNeoplasms, Plasma Cell

Criteria

DISEASE CHARACTERISTICS: * Diagnosis of Waldenstrom's macroglobulinemia (lymphoplasmacytic lymphoma) * Immunoglobulin (Ig) M, IgG, and IgA paraprotein * Measurable monoclonal paraprotein * Failed at least 1 prior first-line therapy (alkylator agent, nucleoside analogue, or rituximab) * CD52-positive tumor determined by either bone marrow immunohistochemistry or flow cytometry PATIENT CHARACTERISTICS: Age * Over 18 Performance status * ECOG 0-2 Life expectancy * At least 6 months Hematopoietic * Absolute neutrophil count ≥ 500/mm\^3 * Platelet count ≥ 25,000/mm\^3 Hepatic * SGOT ≤ 2.5 times upper limit of normal (ULN) * Bilirubin ≤ 2.5 times ULN Renal * Creatinine ≤ 2.5 mg/dL (\> 2.5 mg/dL allowed if due to disease) Other * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective double-method contraception during and for 6 months after study participation * No serious comorbid disease * No uncontrolled bacterial, fungal, or viral infection * No other active malignancy PRIOR CONCURRENT THERAPY: Biologic therapy * See Disease Characteristics * No prior alemtuzumab * More than 3 months since other prior monoclonal antibody therapy Chemotherapy * See Disease Characteristics * More than 21 days since prior chemotherapy Endocrine therapy * More than 21 days since prior steroid therapy Radiotherapy * More than 21 days since prior radiotherapy Surgery * Not specified

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Study Objectives

Study Objectives

Primary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 15 locations

Suspended

Jonsson Comprehensive Cancer Center at UCLA

Los Angeles, United StatesOpen Jonsson Comprehensive Cancer Center at UCLA in Google Maps
Suspended

Rocky Mountain Cancer Centers - Denver Midtown

Denver, United States
Suspended

Robert H. Lurie Comprehensive Cancer Center at Northwestern University

Chicago, United States
Suspended

Greenebaum Cancer Center at University of Maryland Medical Center

Baltimore, United States
Suspended15 Study Centers